Biotech Startups in Auto-immune Disease Field

Part
01
of three
Part
01

Biotech Startups in Autoimmune Disease Field, Part 1

Biotech companies are developing potential novel therapeutics to treat various autoimmune diseases like multiple sclerosis, diabetes, allergies, inflammatory bowel disease, lupus, and others. Further details about the clinical studies for biotech companies listed in rows 2-14 have been provided in the attached spreadsheet.

Summary of findings

  • Arch VeturePartners, Lyell, Milky Way Ventures, and 8VC have invested a total of $40 million in Sonoma Bio.
  • Sandy Macrae, Stéphane Boissel, Adrian Woolfson, Bettina Cockroft, Jason Fontenot, and Roger Kornberg are the key founders of TxCell acquired by Sangamo.
  • Sangamo has generated a total capital of $93.2 million.
  • Some clinical trials of Sangamo are Phase 1&2 Fabry Disease (ST-920), Phase 1&2 Hemophilia A (SB-525), Phase 1&2 Beta Thalassemia (ST-400), Phase 1&2 MPS II (SB-913), and Sickle Cell Disease (BIVV003).
  • Allogenes clinical trials includes "Phase 1 Study, evaluating the safety, efficacy, and cellular kinetics/pharmacodynamics of ALLO-501 in patients with relapsed/refractory large B-Cell lymphoma or follicular lymphoma" and "Phase 1 clinical trial of UCART19 licensed from Servier for relapsed/refractory acute lymphoblastic leukemia (ALL)"

Research Strategy

To provide the requested details for the biotech companies, we scoured through their websites, press releases, media publications, industry reports, and company databases like Crunchbase, Pitchbook, and others. However, we were unable to provide preclinical works and clinical trials of Sonoma Biotherapeutics and Allero Therapeutics, and total funding capital of BTB Pharma. This is because these companies are yet to reach the preclinical and clinical phases of their research. As for BTB Pharma's funding total, we searched its website, press releases, media publications and company databases such as Crunchbase and Zoominfo. However, these strategies were futile. We only found information about the company's investors and revenue among others but nothing about its funding amounts. It was also noted that many European companies did not initiate clinical trials in the United States. Hence, we were unable to identify any ongoing or past clinical studies from the official US clinical trials' database. Consequently, we entered N/A in columns G and H. We have provided the requested details about the biotech companies in the attached spreadsheet.
Part
02
of three
Part
02

Biotech Startups in Autoimmune Disease Field, Part 2

Biotech companies are developing potential novel therapeutics to treat various autoimmune diseases like multiple sclerosis, diabetes, allergies, asthma, inflammatory bowel disease, lupus, myocarditis, and others. We have presented the details about the clinical studies for biotech companies listed in rows 15-27 of the attached spreadsheet.

Summary of Findings

Research Strategy

We were able to compile details for all biotech companies by referencing their websites, press releases, media publications, industry reports, and industry database sites like Crunchbase, Pitchbook, Linkedin, and others.
It is noted that many companies belonging to Europe did not initiate clinical trials in the United States. Further, we could not identify any ongoing or past clinical studies from the official US clinical trials database. Hence, we entered N/A for the same and presented the details about any clinical studies found for the company in columns G and H.
Part
03
of three
Part
03

Biotech Startups in Autoimmune Disease Field, Part 3

Lines 28 through 34 and 39 through 34 of the attached spreadsheet contain details of the research being conducted by the listed biotech firms and research centers.

The research team was unable to locate details for each cell. After searching the company website and sites like Crunchbase and government databases for details about funding and research projects, the research team then searched for press releases, interviews and news reports that may contain information about the companies projects.

In some cases, information was not available, likely because the company was so new or was operating in stealth mode and had not made information publicly available. For example, w only found limited information about Artus Therapeutics, which was started in 2019 and is operating in stealth mode. The company's website is coming soon and provides no details about the company. Research in some companies, such as Xilio Therapeutics, formerly Akrevia Therapeutics, is still in pretrial phase, with no clinical trials started.
Sources
Sources

From Part 03